Abstract
Hospital-acquired pneumonia is a common complication that continues to have a poor cure rate in some patients with intravenous therapy alone. Aerosolized antibiotics are theoretically attractive in an attempt to optimize lung concentrations of antibiotics. Limited data suggest that aerosolized aminoglycosides or colistin in addition to intravenous therapy results in good response rates in patients with multidrug-resistant organisms or nonresponding pneumonia. Adverse events can occur, especially with colistin. When used, care should be taken to properly compound and administer aerosolized antibiotics to ensure tolerability and good drug delivery.
MeSH terms
-
Administration, Inhalation
-
Aerosols
-
Aminoglycosides / pharmacokinetics*
-
Aminoglycosides / therapeutic use
-
Anti-Bacterial Agents / pharmacokinetics*
-
Anti-Bacterial Agents / therapeutic use
-
Colistin / adverse effects
-
Colistin / pharmacokinetics*
-
Colistin / therapeutic use
-
Cross Infection / complications
-
Cross Infection / drug therapy*
-
Cross Infection / microbiology
-
Drug Administration Schedule
-
Drug Dosage Calculations
-
Drug Resistance, Multiple, Bacterial
-
Humans
-
Intensive Care Units
-
Lung / drug effects*
-
Lung / microbiology
-
Lung / physiopathology
-
Nebulizers and Vaporizers
-
Pneumonia, Ventilator-Associated / complications
-
Pneumonia, Ventilator-Associated / drug therapy*
-
Pneumonia, Ventilator-Associated / microbiology
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / physiology
-
Randomized Controlled Trials as Topic
-
Retrospective Studies
-
Treatment Outcome
Substances
-
Aerosols
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Colistin